Influenza Vaccines Clinical Trial
Official title:
"Myths and Facts" About the Flu: Health Education Campaigns Can Reduce Vaccination Intentions
Objectives: To determine whether people systematically misremember the “myths” (false information) as true, and to assess effects on perceptions of risk and behavioral intentions.
| Status | Completed |
| Enrollment | 175 |
| Est. completion date | June 2005 |
| Est. primary completion date | |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 26 Years |
| Eligibility |
Inclusion Criteria: - Must be able to read and write fluent English Exclusion Criteria: |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training
| Country | Name | City | State |
|---|---|---|---|
| Canada | Rotman School of Management, University of Toronto | Toronto | Ontario |
| United States | University of Michigan | Ann Arbor | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| University of Michigan |
United States, Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Memory for truth of information in a flyer. | |||
| Secondary | Intention to get flu vaccine in upcoming season. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03246100 -
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado
|
N/A | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT02761551 -
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates
|
N/A | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Completed |
NCT03735147 -
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
|
Phase 4 | |
| Completed |
NCT02831608 -
Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis
|
Phase 4 | |
| Completed |
NCT02560909 -
Adjuvanted Influenza Vaccine in Stem Cell Transplant
|
Phase 4 | |
| Withdrawn |
NCT01623232 -
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
|
Phase 1/Phase 2 | |
| Completed |
NCT00961337 -
Evaluation of a School-based Influenza Vaccination Program
|
Phase 4 | |
| Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
| Completed |
NCT00222638 -
Influenza Vaccination and Oral Anticoagulant Therapy
|
Phase 4 | |
| Active, not recruiting |
NCT03734237 -
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
|
Phase 4 | |
| Completed |
NCT01013675 -
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly
|
Phase 2 | |
| Completed |
NCT00306995 -
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
|
Phase 2 | |
| Completed |
NCT01310413 -
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
|
Phase 3 | |
| Completed |
NCT00449670 -
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults
|
Phase 3 | |
| Completed |
NCT01788228 -
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
|
Phase 3 | |
| Recruiting |
NCT05521763 -
Influenza Vaccine Uptake Among Healthcare Workers
|
N/A | |
| Completed |
NCT00718120 -
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
|
Phase 3 | |
| Completed |
NCT00430521 -
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
|
Phase 2 |